Agios’ Phase III Data Move It Closer To First Therapy For Rare Anemia
Executive Summary
Strong top-line efficacy in pyruvate kinase deficiency patients who don’t receive regular transfusions looks approvable, analysts say, but Agios will await data in regularly transfused patients.